论文部分内容阅读
目的探讨口服加巴喷丁治疗原发性三叉神经痛的疗效及不良反应。方法将158例原发性三叉神经痛患者随机分为加巴喷丁组和卡马西平组。加巴喷丁组78例,口服加巴喷丁后,将剂量调整到缓解疼痛为止,维持量一般为900～1200 mg。卡马西平组80例,口服卡马西平.调整剂量到缓解疼痛为止,维持量一般为600 mg。治疗后1个月,观察两组患者的疼痛缓解程度以及服药后的不良反应。结果加巴喷丁组和卡马西平组疼痛的总有效率分别为76.9%与77.2%。两组治疗效果的差异无统计学意义(P>0.05),但加巴喷丁组副作用发生率较低。结论加巴喷丁治疗原发性三又神经痛与卡马西平的效果相当,是治疗原发性三叉神经痛等神经病理性疼痛较好的药物。
Objective To investigate the efficacy and adverse reactions of oral gabapentin in the treatment of primary trigeminal neuralgia. Methods 158 patients with primary trigeminal neuralgia were randomly divided into gabapentin group and carbamazepine group. In the gabapentin group, 78 patients received oral gabapentin, and the dose was adjusted to relieve the pain until the maintenance dose was generally 900 to 1200 mg. Carbamazepine 80 cases, oral carbamazepine.Adjust the dose to ease the pain so far, the maintenance dose is generally 600 mg. One month after treatment, the degree of pain relief and the adverse reactions after taking the medicine were observed. Results The total effective rates of gabapentin and carbamazepine pain were 76.9% and 77.2%, respectively. There was no significant difference in therapeutic effect between the two groups (P> 0.05), but the incidence of side effects was lower in the gabapentin group. Conclusion Gabapentin has the same effect as carbamazepine in the treatment of primary trigeminal neuralgia and is a good drug for the treatment of neuropathic pain such as primary trigeminal neuralgia.